On the contrary, mutations in spliceosome genes are more common in MDS and AML-MRC [37,38], while mutations in transcriptional factors, such as RUNX1 and CEBPA, and activating signaling genes, such as NRAS and FLT3, are more common in AML-MRC [8,9]. This evidence concerns the gene CEBPA and acute myeloid leukemia.